Work

Cabozantinib Monotherapy for Metastatic Renal Cell Carcinoma Involving Hemodialysis: Two Case Reports

Year: 2026

Type: article

Abstract: Introduction: Data on cabozantinib monotherapy for metastatic renal cell carcinoma in patients requiring hemodialysis are scarce. We present two cases: initiation before hemodialysis with subsequent continuation and initiation during maintenance hemodialysis. Case Presentation: Case 1 was a 77-year-old man with lung metastasis who received cabozantinib after multiple systemic therapies. Cabozantinib was started at 20 mg/day before hemodialysis; hemodialysis began 8 months later, and treatment continued for 59 months with tolerability-guided schedule modification. Case 2 was a 69-year-old man on maintenance hemodialysis who received cabozantinib 20 mg/day for lung and bone metastases. The schedule was changed to alternate-day dosing. Partial response was achieved, but treatment was discontinued after 4 months because of worsening general condition. Conclusion: Cabozantinib was administered with individualized dose adjustment and careful monitoring; further clinical and pharmacokinetic data are needed to establish optimal dosing.

Source: IJU Case Reports

DOI: 10.1002/iju5.70291